Hypertension persisting after pre-eclampsia: a prospective cohort study at Mulago Hospital, Uganda. by Nakimuli, Annettee et al.
Elliott, AM; Namujju, PB; Mawa, PA; Quigley, MA; Nampijja, M;
Nkurunziza, PM; Belisle, JT; Muwanga, M; Whitworth, JAG (2005)
A randomised controlled trial of the effects of albendazole in preg-
nancy on maternal responses to mycobacterial antigens and infant re-
sponses to bacille Calmette-Guerin (BCG) immunisation [ISRCTN32849447].
Bmc Infectious Diseases, 5. p. 115. ISSN 1471-2334
Downloaded from: http://researchonline.lshtm.ac.uk/12093/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
BioMed Central
Page 1 of 8
(page number not for citation purposes)
BMC Infectious Diseases
Open AccessResearch article
A randomised controlled trial of the effects of albendazole in 
pregnancy on maternal responses to mycobacterial antigens and 
infant responses to bacille Calmette-Guérin (BCG) immunisation 
[ISRCTN32849447]
Alison M Elliott*1,5, Proscovia B Namujju1, Patrice A Mawa1, 
Maria A Quigley3,5, Margaret Nampijja1, Peter M Nkurunziza1, 
John T Belisle4, Moses Muwanga2, James AG Whitworth1,5 and the "Mother 
and Baby" study team
Address: 1Uganda Virus Research Institute, P.O. Box 49, Entebbe, Uganda, 2Entebbe Hospital, P.O. Box 29, Entebbe, Uganda, 3National Perinatal 
Epidemiology Unit, Oxford University, Old Road Campus, Headington, Oxford OX3 7LF, UK, 4Department of Microbiology, Colorado State 
University, Fort Collins, Colorado 80523, USA and 5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Email: Alison M Elliott* - alison.tom@infocom.co.ug; Proscovia B Namujju - proscovia.namujju@mrcuganda.org; 
Patrice A Mawa - patrice.mawa@mrcuganda.org; Maria A Quigley - maria.quigley@npeu.ox.ac.uk; 
Margaret Nampijja - nampijjam@myway.com; Peter M Nkurunziza - mrc@mrcuganda.org; John T Belisle - john.belisle@colostate.edu; 
Moses Muwanga - mosesmuwanga2001@yahoo.co.uk; James AG Whitworth - j.whitworth@wellcome.ac.uk
* Corresponding author    
Abstract
Background: Maternal schistosomiasis and filariasis have been shown to influence infant
responses to neonatal bacille Calmette-Guérin (BCG) immunisation but the effects of maternal
hookworm, and of de-worming in pregnancy, are unknown.
Methods: In Entebbe, Uganda, we conducted a randomised, double-blind, placebo-controlled trial
of a single dose of 400 mg of albendazole in the second trimester of pregnancy. Neonates received
BCG. Interferon-gamma (IFN-γ) and interleukin (IL)-5 responses to a mycobacterial antigen (crude
culture filtrate proteins (CFP) of Mycobacterium tuberculosis) were measured in a whole blood assay.
We analysed results for binary variables using χ2 tests and logistic regression. We analysed
continuous variables using Wilcoxon's tests.
Results: Maternal hookworm was associated with reduced maternal IFN-γ responses to CFP
(adjusted odds ratio for IFN-γ > median response: 0.14 (95% confidence interval 0.02–0.83, p =
0.021). Conversely, maternal hookworm was associated with subsequent increased IFN-γ
responses in their one-year-old infants (adjusted OR 17.65 (1.20–258.66; p = 0.013)). Maternal
albendazole tended to reduce these effects.
Conclusion: Untreated hookworm infection in pregnancy was associated with reduced maternal
IFN-γ responses to mycobacterial antigens, but increased responses in their infants one year after
BCG immunisation. The mechanisms of these effects, and their implications for protective
immunity remain, to be determined.
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Background
Bacille Calmette-Guérin (BCG) immunisation is relatively
ineffective against tuberculosis in the tropics, where the
incidence of tuberculosis is high [1]. Helminth infection
induces T-helper-2 responses and production of immu-
noregulatory cytokines and molecules that modulate
responses to both helminths and bystander antigens; T-
helper-1 and cytotoxic responses, required for immunity
to viruses and intracellular bacteria, may be impaired [2].
Recognition of these effects has promoted speculation
that helminth infection contributes to the observed
reduced efficacy of BCG, and increased susceptibility to
tuberculosis, in tropical countries [3]. BCG is often
administered at birth in developing countries, so the
observation that sensitisation to maternal schistosomiasis
or filariasis in utero was associated with reduced inter-
feron (IFN)-γ and increased interleukin (IL)-5 responses
to mycobacterial antigens at one year of age, following
BCG immunisation at birth, is of particular interest [4].
Hookworm is more widespread than schistosomiasis or
filariasis [5], and may also suppress IFN-γ responses, both
to hookworm, and to mycobacterial antigens [6]. Routine
anthelminthic treatment after the first trimester of preg-
nancy, targeting hookworm anaemia, is now advocated,
despite theoretical risks of teratogenicity (seen in animal
models but not in man) [7], as benefits are expected to
outweigh risks. However, the impact of this policy on
other aspects of maternal and infant health has not been
thoroughly investigated [8]. We wished to determine
whether maternal hookworm infection had similar effects
on neonatal responses to BCG to those reported for schis-
tosomiasis and filariasis, and whether any such effects
were removed by treatment for hookworm during preg-
nancy.
Methods
Mothers in the second trimester of pregnancy were
enrolled in a randomised, double-blind, placebo-control-
led trial of albendazole treatment during pregnancy, at
Entebbe Hospital, Uganda, between June and August
2002. The study was designed to examine effects of alben-
dazole treatment in pregnancy on immunological and
disease outcomes in infants. The design was revised when
the World Health Organisation announced new recom-
mendations for treatment of helminths in pregnancy [9].
This paper presents data for the preliminary group of
mothers, enrolled before the change of protocol. Mothers
were included if they were resident in the study area, plan-
ning to deliver in hospital and willing to know their HIV
status. Mothers with haemoglobin below 8 g/dl were
excluded and treated for hookworm and anaemia. Other
exclusion criteria were abnormal pregnancy or history of
adverse reaction to anthelminthic drugs. Before treatment,
mothers were screened for intestinal parasites by the Kato-
Katz method and stool culture [10]; blood was examined
for malaria, microfilariae [11], full blood count and HIV
(within a programme for prevention of mother-to-child
HIV transmission). All eligible mothers were then ran-
domised to treatment with single-dose albendazole (400
mg) or placebo, regardless of whether hookworm was
detected or not. The randomisation sequence was gener-
ated by an independent statistician (MQ), using blocks of
50. Albendazole and matching placebo tablets (Glaxo-
SmithKline, UK) were packaged in identical envelopes,
labelled with the randomisation code. Clinic staff gave
participants the next number in the sequence, in order of
enrolment.
At delivery mothers were asked to provide a second stool
and blood sample; if possible, cord blood was obtained.
Infants were immunised with intradermal BCG
(100,000–330,000 colony forming units; Serum Institute
of India, India). Six weeks after delivery all mothers were
treated with both albendazole and praziquantel. Stool
and blood samples were obtained from infants at one year
of age.
All participants gave written informed consent. Ethical
approval was given by ethics committees of the Uganda
Virus Research Institute, Uganda National Council for Sci-
ence and Technology and London School of Hygiene and
Tropical Medicine.
Immunological assays
The primary outcome measures were immune responses
in mothers and their infants, measured as follows. We
examined stimulated IFN-γ and IL-5 responses in a whole
blood assay, and measured serum levels of regulatory
cytokines (IL-10 and Transforming Growth Factor (TGF)-
β). In the whole blood assay [12], unseparated,
heparinised blood was diluted to a final concentration of
one-in-four using RPMI supplemented with penicillin,
streptomycin and glutamine, plated in 96-well plates, and
stimulated with crude culture filtrate protein of M. tuber-
culosis (CFP) (5 µg/ml), or phytohaemagglutinin (PHA)
(10 µg/ml) (Sigma, UK), or left unstimulated. Superna-
tants were harvested on day 6 and frozen until analysed.
Cytokine concentrations in serum or supernatants were
measured by ELISA (Becton Dickinson, UK). The sensitiv-
ity of the assays was 62.5 pg/ml for TGF-β; 2.5 pg/ml for
IL-10; 7.8 pg/ml for IL-5; 9.4 pg/ml for mothers and 37.5
pg/ml for infants for IFN-γ. Low-level cytokine production
in un-stimulated wells was subtracted from concentra-
tions produced in response to stimulation. Assays for
samples with results above the highest standard were
repeated after dilution.
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Study profileFigure 1
Study profile.
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Statistical methods
Cytokine levels and responses were skewed so quantita-
tive data were analysed using Wilcoxon's tests for paired
or unpaired data as appropriate. A high proportion of
mothers and infants showed positive IFN-γ responses to
CFP. To allow analysis of effects of potential confounding
factors using logistic regression, a binary variable was cre-
ated indicating IFN-γ production below or above the
median response. The sample size for this analysis was
determined by the number of mothers recruited before
the change in study protocol. Our analysis was not typical
of a controlled trial, because our objective was to study
both the effects of maternal helminths (by comparison of
outcomes between mothers with and without helminths)
and the modification of their effects by treatment (in the
trial). Therefore, we first examined the effect of maternal
helminth infection on cytokine responses in mothers at
enrolment, and in their infants when they reached one
year of age, and used the binary variable for high IFN-γ
response to perform an analysis that adjusted for potential
confounding factors using logistic regression. We then
analysed the treatment trial by intention-to-treat: for each
analysis, comparisons were made between albendazole
and placebo recipients, first, for all participants, and sec-
ond, for the sub-group of mothers with hookworm at
enrolment (in whom any effect of treatment was expected
to be greater). We examined the effect of treatment on
responses in the mothers (using samples taken at deliv-
ery); in cord blood; and in one-year-old infants.
Unblinded analyses were conducted by MQ. All other staff
and participants remain blinded to treatment allocation
as follow up continues.
Results
The trial profile is shown in figure 1. At enrolment, moth-
ers' mean age was 23 years; 15/103 (15%) were HIV-pos-
itive; 15/103 (15%) had malaria; 38/101 (38%) had
hookworm, 23/101 (23%) Schistosoma mansoni, 13/101
(13%) Trichuris trichiura, 6/101 (6%) Ascaris lumbricoides,
13/84 (15%) Strongyloides stercoralis and 21/99 (22%)
Mansonella perstans. Of those with hookworm, 28 had
light (1–999 eggs/g), eight moderate (1000–3999 eggs/g)
and two heavy (≥ 4000 eggs/g) infection. Maternal
helminth infection showed expected associations with
younger age (p = 0.027) and lower education (p = 0.002).
Mothers in albendazole and placebo groups were similar
in age, HIV, malaria and helminth prevalence, and base-
line cytokine levels and responses. After delivery the prev-
alence of hookworm was 0/47 (0%) in the albendazole
group and 14/42 (33%) in the placebo group; other
helminths remained similar in the two groups. Among
one-year-olds, 3/63 had hookworm (one whose mother
received albendazole, two placebo), 1/63 had Trichuris
(albendazole-mother) and 1/54 Mansonella (placebo-
mother).
Effects of maternal hookworm on responses mycobacterial antigens in mothers during pregnancy and their one-year-o d in anFigure 2
Effects of maternal hookworm on responses myco-
bacterial antigens in mothers during pregnancy and 
their one-year-old infants. Effects of maternal hookworm 
on IFN-γ responses to culture filtrate proteins of Mycobacte-
rium tuberculosis in (a) mothers at enrolment during preg-
nancy (before receiving study treatment) and (b) their one-
year-old infants, who received BCG immunisation at birth. 
IFN-γ responses shown are net production: low-level 
cytokine production in un-stimulated wells was subtracted 
from concentrations produced in response to stimulation to 
give a measure of antigen-specific response. "No worms": no 
helminths detected in stool or blood sample from mother 
either in pregnancy or at delivery. "Hookworm": mother had 
hookworm in pregnancy. Boxes show median value, 25th and 
75th centiles; whiskers show lower and upper adjacent val-
ues and dots indicate outside values. P values <0.10 (Wil-
coxon's rank sum test) are shown.
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Immunological findings
Kato-Katz stool results for mothers at enrolment and all
cytokine results were available for 90/103 mothers at
enrolment, 79/93 at delivery (72 with results at both time
points), and 57/63 one-year-olds. Whole blood assay data
were missing when assays were unsatisfactory, and sam-
ples insufficient for repeats. Analysis of cord blood sam-
ples was restricted to 48/52 samples where mixing with
maternal blood was excluded using an alkaline denatura-
tion test [13]; serum cytokine results were complete for
these 48 samples. Whole blood assay data were complete
for only 33 of these cord blood samples: only five had a
positive IFN-γ response, and one a positive IL-5 to CFP;
therefore cord blood whole blood assay results are not
presented further here.
Effects of maternal helminth infection on cytokine 
responses in mothers at enrolment and in their one-year-
old infants
At enrolment, all helminth species were associated with
lower maternal IFN-γ responses to CFP. This effect was
most marked, and statistically significant, for hookworm
(median 10 (interquartile range 0, 162) pg/ml compared
to 173 (4, 471) pg/ml, p = 0.048) (Figure 2(a)). Five
mothers had a positive IL-5 response to CFP; all had
helminth infections.
Among one-year-old infants, the opposite effect was seen:
IFN-γ responses to CFP were higher, for all species of
helminth, among infants of mothers who had helminth
infections in pregnancy. Despite effective treatment of
maternal hookworm in approximately half the cases, this
effect was also strongest for hookworm (median IFN-γ
production 737 (220, 1805) pg/ml for infants of mothers
with hookworm; 75 (24, 228) pg/ml for infants of moth-
ers without helminths, p = 0.020) (Figure 2(b)). Nine
infants had positive IL-5 responses to CFP; 6 had mothers
with helminth infection.
It was considered possible that the associations between
maternal hookworm and responses to CFP in the moth-
ers, or in their infants, might be explained by confounding
factors such as co-infection with other pathogens (mater-
nal malaria or HIV), maternal age, socioeconomic factors,
or maternal BCG immunisation. We investigated this by
creating binary variables for IFN-γ production below and
above the median level of response in mothers and
infants. This allowed us to examine associations between
such factors and responses to CFP (Table) and to adjust
for their effects using logistic regression. The observed
associations between maternal hookworm and IFN-γ
responses to CFP in mothers and their infants were not
explained by any of the variables examined: odds ratios
for the associations between maternal hookworm and
high IFN-γ responses to CFP, adjusted for maternal age,
HIV status, malaria parasitaemia, education, BCG scar and
schistosomiasis were, for mothers at enrolment: 0.14
(95% confidence interval 0.02–0.83, p = 0.021); for
infants at one year of age: 17.65 (95% CI: 1.20–258.66, p
= 0.013).
Analysis of the trial: effects of maternal treatment with 
albendazole on cytokine responses to CFP
Mothers who received albendazole had an increase in
IFN-γ response to CFP (median increase +26 (-7, +293)
pg/ml), whereas placebo recipients did not (0 (-279, +73)
pg/ml) (p = 0.019)). Among hookworm-infected moth-
ers, corresponding increases were +55 (0, +386) pg/ml for
albendazole, and 0 (-44, +81) pg/ml for placebo recipi-
ents (p = 0.055). Thus, treatment of hookworm in the
mothers resulted in a profile of CFP responses that was
similar to the "no helminth" group (Figure 3a). No effects
of albendazole were observed on maternal IL-5 responses.
Conversely, IFN-γ responses to CFP were lower in infants
of hookworm-infected mothers who received albendazole
than in those whose mothers received placebo (Figure 3b)
and IL-5 responses less frequent, although these effects
were not statistically significant. The BCG scar diameter in
one-year-old infants followed a similar pattern, being sig-
nificantly smaller in infants of hookworm-infected moth-
ers who received albendazole (2.0 (1.0, 3.0) mm) than in
those whose mothers received placebo (3.5 (2.8, 4.0)
mm; p = 0.026). BCG scar diameter showed a positive cor-
relation with the IL-5 response to CFP (ρ = 0.32, p =
0.011) but not with the IFN-γ response.
Non-specific immune responses
In most analyses, maternal helminths and albendazole
treatment showed no effect on PHA responses or serum
cytokine levels. However, cord blood IL-10 was lower for
albendazole than placebo recipients, and this effect was
statistically significant among hookworm mothers,
(median 3 (0, 5) pg/ml versus 12 (4, 18) pg/ml, p =
0.031). TGF-β was detected in cord blood only for three
mothers, all placebo recipients, of whom two were hook-
worm-infected.
Discussion
We present results of a preliminary study, the principal
limitations of which are small numbers and the wide con-
fidence intervals of some results. However, interesting
contrasts were observed with previous reports and, within
the study, between mothers and infants. To our knowl-
edge, this is the first report of the immunological effects of
treating helminths in pregnancy and, as such, suggests fur-
ther important avenues of research.
Our study was designed to examine the effects of active
helminth infection through parasitological examination
BMC Infectious Diseases 2005, 5:115 http://www.biomedcentral.com/1471-2334/5/115
Page 6 of 8
(page number not for citation purposes)
of stool and blood samples, and the effects of albendazole
treatment in pregnancy. Examination of a single stool
sample is less than 100% sensitive for helminth infection
[14], so some infected mothers would be misclassified as
uninfected. This would lead to underestimates of
helminth effects; thus we expect that the results presented
for comparisons between mothers with and without
hookworm and their infants are conservative. This mis-
classification would not affect the validity of the results of
the trial (effects of albendazole vs placebo regardless of
helminth infection status); or of the sub-group analysis
(albendazole vs placebo) in mothers who had positive
initial stool results for hookworm.
The most striking effects were observed for maternal
hookworm, which was associated with reduced IFN-γ
responses to the mycobacterial antigen, CFP, in the moth-
ers, and with increased IFN-γ responses, following BCG
immunisation, in their infants. These effects were not
explained by measured confounding factors. Confound-
ing factors not measured in this study might include
genetic factors, which affect susceptibility to helminth
infections [5]. Thus adults found to be helminth-egg-pos-
itive might be immuno-genetically different from those
found to be egg-negative and immuno-genetic traits trans-
mitted from mother to infant might possibly explain the
effects observed. For example, a trait associated with
stronger type 1 immune responses might lead to increased
susceptibility to hookworm in the mothers and stronger
responses to BCG in their infants. However, this explana-
tion seems unlikely: the effects observed were reduced by
albendazole treatment in pregnancy suggesting that an
effect of active helminth infection may be a more proba-
ble explanation of the results.
The suppressive effect observed in mothers was in keeping
with the results of studies in laboratory animals indicating
suppression of type 1 responses to mycobacteria in the
presence of helminths [15-17] and reduced efficacy of
BCG against challenge with virulent Mycobacterium tuber-
culosis in mice co-infected with Schistosoma mansoni [18].
In humans, studies addressing the effects of helminths on
immune responses to mycobacteria (measured as tuber-
culin skin test responses, or as responses to mycobacterial
antigens in vitro), have had variable results, perhaps
related to choice of comparison groups, or differences in
effect by species or intensity of helminth infection [19-
22]. In this randomised, placebo-controlled trial, the
increase in response among mothers who received alben-
dazole supports a causal role of hookworm in suppression
of the response. Studies in both laboratory animals
[16,17] and humans [20,23,24], including a placebo-con-
trolled trial of albendazole treatment prior to BCG immu-
nisation among helminth-infected, Ethiopian adults [24],
have indicated a suppressive effect of helminths on the
Effects of maternal hookworm and albendazole treatment on responses mycobacterial antigens in mothers at delivery andtheir on -year- ld infantsFigure 3
Effects of maternal hookworm and albendazole 
treatment on responses mycobacterial antigens in 
mothers at delivery and their one-year-old infants. 
Effects of maternal hookworm, and maternal treatment with 
albendazole during pregnancy, on IFN-γ responses to culture 
filtrate proteins of Mycobacterium tuberculosis in (a) mothers 
at delivery and (b) their one-year-old infants, who received 
BCG immunisation at birth. IFN-γ responses shown are net 
production: low-level cytokine production in un-stimulated 
wells was subtracted from concentrations produced in 
response to stimulation to give a measure of antigen-specific 
response. "No worms": no helminths detected in stool or 
blood sample from mother either in pregnancy or at delivery. 
"Hk, plac": mother had hookworm in pregnancy and received 
placebo. "Hk, alb": mother had hookworm in pregnancy and 
received albendazole. Boxes show median value, 25th and 
75th centiles; whiskers show lower and upper adjacent val-
ues and dots indicate outside values. P values <0.10 (Wil-
coxon's rank sum test) are shown comparing a no worms vs 
hookworm, placebo; b hookworm, placebo vs albendazole; c 
no worms vs hookworm, whether placebo or albendazole.
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immune response elicited by BCG. The contrasting effect
of prenatal exposure to maternal hookworm observed in
our infants was particularly unexpected in view of the ear-
lier report of a suppressive effect of prenatal exposure
schistosomiasis and filariasis on the IFN-γ response fol-
lowing BCG at birth [4]. One possible explanation is that
immunological effects differ between helminth species.
On the other hand, the earlier study of prenatal exposure
did not include uninfected mothers, but compared infants
sensitised, or not sensitised to helminth antigens in utero:
suppression of IFN-γ responses to mycobacterial antigens
following BCG immunisation was observed in the sensi-
tised infants. Thus the nature of the exposure in utero, per-
haps related to the species or intensity of helminth
infection, may be an important factor.
Our results for IFN-γ could mean that light-to-moderate
maternal hookworm infection induced a "better"
response to BCG. However, noting that IL-5 responses
were more frequent, and BCG scars largest, in the
untreated hookworm group, and that scar size correlated
with IL-5 production, an alternative hypothesis might be
considered. Immunological factors in neonates, such as
the elevation of regulatory cytokines suggested by our
results for cord blood, may lead to delayed control of BCG
replication, a larger "dose" of mycobacteria, and less selec-
tive, more destructive cytokine responses, which may, or
may not, be protective [25-27]. This hypothesis will be
investigated in further studies.
Conclusion
Maternal helminths, especially hookworm, were associ-
ated with suppression of maternal responses to the myco-
bacterial antigen, CFP, and this effect was largely removed
by maternal treatment with albendazole. These results,
and the elevated levels of IL-10 in cord blood of mothers
with untreated hookworm, were in keeping with current
hypotheses regarding the immunoregulatory effects of
helminth infections.
By contrast, the association between maternal hookworm
and an elevated IFN-γ response to CFP in infants one year
after BCG immunisation was unexpected. The mechanism
of this effect, and its implications for protective immu-
nity, need to be explored.
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